Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

YM BioSciences Inc. (YMB)

  Print      Mail a friend

Wednesday 28 September, 2005

YM BioSciences Inc.

Research Update

YM BioSciences partner, Oncoscience AG, reports update of pediatric

    brain cancer data


    - Nimotuzumab (Theraloc; TheraCIM h-R3) Phase II results awarded best

    poster prize at the 37th congress of the International Society of

    Paediatric Oncology -


    MISSISSAUGA, ON, Sept. 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that

updated data from a Phase II monotherapy trial of nimotuzumab in children with

resistant or relapsed high-grade gliomas (brain cancers) were reported in a

poster presented on September 23rd, 2005 at the 37th Congress of The

International Society of Paediatric Oncology in Vancouver, Canada. Nimotuzumab

produced cytotoxic efficacy and evidence of survival benefit in children with

heavily pretreated relapsed high grade gliomas, especially those with diffuse,

intrinsic pontine glioma.

    The presentation updated data originally contained in a press release by

YM BioSciences issued on February 28th, 2005 that described results in 17

evaluable children. The updated data now includes results from 34 children of

which 27 were evaluable at an eight week assessment. The trial design

evaluates the children after eight weeks (induction) of therapy and after week

21 (consolidation) of therapy.

    Nine of the 27 patients evaluable following induction had brain-stem

(diffuse intrinsic pontine) glioma, a treatment-resistant tumor. In the nine

evaluable patients with pontine glioma, five demonstrated clinical benefit at

week eight; four with Stable Disease (SD) and one with Partial Response (PR).

At the same time-point, three of the 18 remaining patients diagnosed with high

grade gliomas (grades III/IV) were assessed with clinical benefit (SD) at week


    Of the five patients (all pontine gliomas) who went on to complete the

consolidation period of five months of treatment, two who were evaluated at

induction with SD are now assessed as PR.

    Survival in the eight patients who derived clinical benefit post-

induction is as follows:



                                 Pontine Glioma      Other High-Grade Gliomas


    Months of Survival       15.5+; 14+; 11; 10; 3+         11+; 2.5; 8+


    (+ remains alive)

    Median survival of the children who did not respond to nimotuzumab was

    1.3 months.


    The conclusions of the presentation were:


    -   Nimotuzumab has cytotoxic efficacy in heavily pretreated relapsed

        high grade gliomas, especially in diffuse, intrinsic pontine glioma.


    -   Repeated application of nimotuzumab is well tolerated and safe; no

        severe hematological or non-hematological side effects were reported.


    -   High quality of life with long intervals of home care, attending the

        school or kindergarten.


    -   A phase III study on the effectiveness of nimotuzumab in newly

        diagnosed intrinsic pontine glioma concomitant with radiotherapy in

        children and adolescents is planned.


    'This study demonstrated the strong anti-tumour activity of nimotuzumab

in the absence of the toxicities, namely rash and diarrhea, normally

associated with other drugs in this class,' said Dr. Paul Keane, Director of

Medical Affairs at YM BioSciences.

    The poster presentation was awarded best poster prize at the conference

in the section 'Experimental Therapeutics'. Posters were judged based on

scientific merit, visual presentation and the potential significance of the

clinical research.


    About Oncoscience AG

    Oncoscience AG is a private biotech company based in Germany and is

focused in Oncology (Theraloc), Organ Transplantation (Lifor) and Tumor tissue

banking including research in Genomics/Proteomics.


    About YM BioSciences

    YM BioSciences Inc. is a cancer product development company. Its lead

drug, tesmilifene, is a small molecule chemopotentiator currently completing

enrollment in a 700-patient pivotal Phase III trial in metastatic and

recurrent breast cancer. Published results from tesmilifene's first Phase III

trial in the same indication demonstrated a substantial increase in survival

for women treated with the combination of tesmilifene and chemotherapy

compared to chemotherapy alone, demonstrating that tesmilifene significantly

enhanced the therapeutic effect of chemotherapy. In addition to tesmilifene,

the Company is developing nimotuzumab, an anti-EGFr humanized monoclonal

antibody in a number of indications. YM BioSciences is also developing its

anti-GnRH, anti-cancer vaccine, Norelin(TM), for which Phase II data have been

released. In May 2005, the Company acquired DELEX Therapeutics Inc., a private

clinical stage biotechnology company developing AeroLEF(TM), a unique

inhalation delivered formulation of the established drug, fentanyl, to treat

acute pain including cancer pain. This product has completed a Phase IIa trial

with positive results and randomized a Phase IIb pain trial has been cleared

to start. The Company also has a broad portfolio of preclinical compounds

shown to act as chemopotentiators while protecting normal cells.


    Except for historical information, this press release may contain forward-

looking statements, which reflect the Company's current expectation regarding

future events. These forward looking statements involve risk and

uncertainties, which may cause but are not limited to, changing market

conditions, the successful and timely completion of clinical studies, the

establishment of corporate alliances, the impact of competitive products and

pricing, new product development, uncertainties related to the regulatory

approval process and other risks detailed from time to time in the Company's

ongoing quarterly and annual reporting.


    For further information: James Smith, the Equicom Group Inc., Tel.

(416) 815-0700 x 229, Fax (416) 815-0080, Email: jsmith(at);

Carolyn McEwen, YM BioSciences Inc., Tel. (905) 629-9761, Fax (905) 629-4959,

Email: ir(at)

    (YM. YMI)



a d v e r t i s e m e n t